Zealand Pharma A/S (ZEAL) 2018年年度报告「NASDAQ」.pdf

1、Clear path aheadZealand Pharma Annual Report 2018Company reg.no.20045078Anders Stensbjerg Kristensenlives with type 1 diabetesChanging lives with next generation peptide therapeuticsOur ambition is to be a world leader in treating specialty gastrointestinal and metabolic diseases.2Zealand Pharma Ann

2、ual Report 20182Zealand Pharma Annual Report 2018ContentsAbout Zealand PharmaZealand in brief 5Shareholder Letter 62018 Achievements 9Financial highlights and 2019 guidance 10Consolidated Key Figures 112019 Objectives 12Our Ambition and Business Model 14Pipeline Overview 16Other Programs Rare Diseas

3、es:dasiglucagon for congenital hyperinsulinism 28Partnered Programs:Obesity/type 2 diabetes 29Our Established Peptide Platform Pre-Clinical Projects 30Our programsReducing the burden of short bowel syndrome Mikes story 18About short bowel syndrome 20Glepaglutide for short bowel syndrome 22ZP7570(GLP

4、-1/GLP-2)for short bowel syndrome 23Improving the lives of people with insulin-dependent diabetes Anders and Finns story 24Dasiglucagon for severe hypoglycemia in diabetes 26Dasiglucagon for fully automated management of type 1 diabetes 27Corporate mattersCorporate Governance 33Corporate Social Resp

5、onsibility 36Our People 37Risk Management and Internal Control 38Financial Review 41Shareholder Information 44Board of Directors 46Corporate Management 48Other informationSources 103Addresses(company information)103Shareholder letter2018 has been a remarkable year,with substantial advancement of our

6、 fully-owned medicines in development.Read more onpage 6Pipeline overviewWe have four late stage programs with potential to launch in two to four years,and a promising early pipeline.Read more onpage 16Financial highlightsA strong financial position to enable full-speed development of our pipeline.R